Author

Kunal Tomar

Humboldt-Universität zu Berlin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Assay:proteomics· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

Aarthi Nivasini MaheshiD· 1 shared Ahmed M. MamdouhiD· 1 shared Alexandre PuissantiD· 1 shared Brandon Douglas BrowniD· 1 shared Camille LobryiD· 1 shared Cheryl Gek Teng Chan· 1 shared Chuqi WangiD· 1 shared Edward AyoubiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aarthi Nivasini MaheshORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

BIRC5 dependency defines a targetable vulnerability in TP53 mutant acute myeloid leukemia

Ahmed M. Mamdouh, Fang Qi Lim, Yang Mi, Elyse A. Olesinski, Shaista Shabbir Jasdanwala, Xiao Xian Lin, Edward Ayoub, Jordan Yong Ming Tan, Karanpreet Singh Bhatia, Yichen Wang, Shradha Garnaik, Kunal Tomar, Valeriia Sapozhnikova, Cheryl Gek Teng Chan, Chuqi Wang, , Shruti Bhatt

This study identifies BIRC5 as a targetable vulnerability in TP53 mutant AML, showing that survivin/IAP inhibitors can overcome therapy resistance.

bioRxiv · May 17, 2025 · PreprintCancer Biology